Display options
Cite
Edelman MJ, Lapidus R, Feliciano J, et al. Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors. Cancer Chemother Pharmacol. 2016;78(5):969doi: 10.1007/s00280-016-3159-7.
Edelman, M. J., Lapidus, R., Feliciano, J., Styblo, M., Beumer, J. H., Liu, T., & Gobburu, J. (2016). Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors. Cancer chemotherapy and pharmacology, 78(5), 969. https://doi.org/10.1007/s00280-016-3159-7
Edelman, Martin J, et al. "Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors." Cancer chemotherapy and pharmacology vol. 78,5 (2016): 969. doi: https://doi.org/10.1007/s00280-016-3159-7
Edelman MJ, Lapidus R, Feliciano J, Styblo M, Beumer JH, Liu T, Gobburu J. Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors. Cancer Chemother Pharmacol. 2016 Nov;78(5):969. doi: 10.1007/s00280-016-3159-7. PMID: 27677624.
Copy Download .nbib Format: NLM
Share it on

Cancer Chemother Pharmacol. 2016 Nov;78(5):969. doi: 10.1007/s00280-016-3159-7.

Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors.

Cancer chemotherapy and pharmacology

Martin J Edelman, Rena Lapidus, Josephine Feliciano, Miroslav Styblo, Jan H Beumer, Tao Liu, Jogarao Gobburu

Affiliations

  1. University of Maryland Greenebaum Cancer Center, 22 S. Greene Street, Baltimore, MD, 21201, USA. [email protected].
  2. University of Maryland Greenebaum Cancer Center, 22 S. Greene Street, Baltimore, MD, 21201, USA.
  3. Department of Nutrition, University of North Carolina, Chapel Hill, NC, USA.
  4. Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
  5. Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.
  6. Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  7. University of Maryland School of Pharmacy, Baltimore, MD, USA.

PMID: 27677624 DOI: 10.1007/s00280-016-3159-7

[No abstract available.]

Publication Types